By measuring reference decay data for a suite of novel therapeutic nuclides (uranium -230, actinium-225, bismuth-213 and thorium-226) to be used in alpha-immunotherapy, the JRC has improved the accuracy of the doses received during cancer treatment.
The JRC has developed a new reference material to support the monitoring of chronic myelogenous leukaemia (CML), a cancer of the white blood cells. In the EU, about 9600 new patients per year are diagnosed, and CML accounts for 70% of all childhood leukaemia cases.
Chronic myelogenous leukaemia (CML) is a cancer of the white blood cells. In the EU about 9600 new patients per year are diagnosed and CML accounts for 70% of all childhood leukaemia cases. CML can currently not be cured, but kept under control with specific enzyme inhibitors. Regular monitoring of the CML patient is needed to ensure optimal treatment of the patient.